VentriPoint Announces Appointment of New Chief Financial Officer
(firmenpresse) - SEATTLE, WASHINGTON -- (Marketwire) -- 03/01/13 -- VentriPoint Diagnostics Ltd. (TSX VENTURE: VPT) (OTCQX: VPTDF) announces today that it has appointed Ellen Briant as the Company's Chief Financial Officer and Corporate Secretary. Ms. Briant is a seasoned finance professional with 15 years of experience in corporate finance, project finance, banking, relationship management and accounting.
"We are delighted that Ellen has joined the VentriPoint Team as Chief Financial Officer. Her financial and transactional background will serve the Company well as we continue to launch new products, build revenue, establish partnerships and grow the Company," stated Dr. George Adams, President and Chief Executive Officer of VentriPoint.
Previously she worked at Spire Sharwood (previously Sharwood & Company) providing corporate finance advisory services for private placement and merger & acquisition transactions to mid-market and start-up companies. She was the Vice-President & Director, Private Placements Group for Deloitte & Touche, where she arranged senior and mezzanine debt financing and provided financial strategy and advisory services for various sized clients, including government entities and greenfield projects. Prior to that she worked in the corporate banking group at Scotiabank and the financial services audit group of Ernst & Young.
Ms. Briant obtained a B.A. from Queen's University, a B.Comm. from the University of Windsor, and a M.B.A. from the Richard Ivey School of Business at the University of Western Ontario. As well, she earned the designation of Chartered Accountant (C.A.) from The Institute of Chartered Accountants of Ontario.
The Company has accepted the resignation of Chris Deaton. "Chris has successfully led the Company through the upgrading of our financial systems to allow growth as a revenue company. VentriPoint thanks her contributions to the Company's success and wishes her well in her new position," remarked Treuman Katz, Chairman of VentriPoint. Ms. Deaton will be available to the Company to effect a smooth transition.
The Board of Directors has granted incentive stock options for the purchase of up to 250,000 shares at a price of $.10 per share exercisable on or before February, 27 2018 to Ms. Briant. The options are subject to a stock option plan.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults and Pulmonary Arterial Hypertension are the first applications in a suite of applications for all major heart diseases including cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ tool and the Company is pursuing the US-FDA marketing clearance through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Contacts:
VentriPoint Diagnostics Ltd.
Dr. George Adams
CEO
(206) 283-0221 ext. 401
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.03.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 234867
Anzahl Zeichen: 0
contact information:
Town:
SEATTLE, WASHINGTON
Kategorie:
Medical Devices
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VentriPoint Announces Appointment of New Chief Financial Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
VentriPoint Diagnostics Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
